1. Home
  2. LFCR vs RCKT Comparison

LFCR vs RCKT Comparison

Compare LFCR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifecore Biomedical Inc.

LFCR

Lifecore Biomedical Inc.

N/A

Current Price

$6.37

Market Cap

241.8M

Sector

Health Care

ML Signal

N/A

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

N/A

Current Price

$2.40

Market Cap

239.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LFCR
RCKT
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.8M
239.3M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
LFCR
RCKT
Price
$6.37
$2.40
Analyst Decision
Hold
Buy
Analyst Count
5
14
Target Price
$6.28
★ $8.58
AVG Volume (30 Days)
430.4K
★ 2.0M
Earning Date
11-04-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.37
EPS
N/A
★ 0.66
Revenue
★ $557,559,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.47
$915.60
P/E Ratio
★ N/A
$3.95
Revenue Growth
★ 6.36
N/A
52 Week Low
$3.63
$2.17
52 Week High
$8.98
$5.45

Technical Indicators

Market Signals
Indicator
LFCR
RCKT
Relative Strength Index (RSI) 60.56 47.85
Support Level $6.32 $2.17
Resistance Level $6.50 $2.73
Average True Range (ATR) 0.06 0.18
MACD -0.07 0.05
Stochastic Oscillator 21.95 64.00

Price Performance

Historical Comparison
LFCR
RCKT

About LFCR Lifecore Biomedical Inc.

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: